Biodesix stock maintains Buy rating at Canaccord after strong Q3 results

Biodesix (BDSX) reported mixed third-quarter 2025 results, with revenue of $21.8 million surpassing expectations due to improved payer dynamics, but a significant EPS miss of -$1.16 against a -$0.06 forecast. Despite operating with $73.47 million in debt and current unprofitability, Canaccord Genuity maintained a Buy rating and a $20.00 price target, citing the company's raised full-year revenue guidance and reaffirmed target for positive adjusted EBITDA in Q4 2025, positioning it for long-term growth in pulmonology and primary care markets.

Analysis

Biodesix (BDSX) delivered mixed third-quarter 2025 results, reporting revenue of $21.8 million, which surpassed the $20.83 million forecast due to improved payer dynamics and average selling prices. This revenue beat, however, was overshadowed by a substantial EPS miss of -$1.16 against a forecasted -$0.06. Despite the earnings shortfall, Canaccord Genuity maintained its Buy rating and a $20.00 price target, implying significant upside from the current $6.34.

The company's revenue growth trajectory remains robust, with a 25.7% increase over the last twelve months, bringing total revenues to $76.56 million. Management raised its full-year 2025 revenue guidance and reaffirmed its target for positive adjusted EBITDA in Q4 2025, indicating confidence in future operational efficiency. However, InvestingPro data reveals a significant debt load of $73.47 million and current unprofitability, with an EBITDA of -$28.08 million, despite a healthy current ratio of 2.14.

Canaccord Genuity noted that the disruption from Biodesix's strategic shift is stabilizing, with its focus on pulmonology and primary care markets positioning it for sustained long-term revenue growth. The ongoing commercial restructuring, targeting 93-97 sales representatives by year-end 2025, supports this expansion. Interim CLARIFY study results also contribute to the positive outlook for its diagnostic offerings.

Key Decisions for Investors

• Investors should closely monitor Biodesix's progress towards achieving its reaffirmed target of positive adjusted EBITDA in Q4 2025, as sustained profitability is crucial for long-term value creation.
• Evaluate the company's ability to manage its $73.47 million debt burden and assess its impact on future capital allocation and financial flexibility, especially given its current unprofitability.
• Assess the sustainability of the revenue growth drivers, such as improved payer dynamics and commercial restructuring, while considering the implications of the significant EPS miss on operational efficiency and cost control.